Skip to content

Transcutaneous auricular Vagus Nerve Stimulation for the treatment of myoarthropatic symptoms in patients with craniomandibular dysfunction – a randomized and controlled pilot trial

Transcutaneous auricular Vagus Nerve Stimulation for the treatment of myoarthropatic symptoms in patients with craniomandibular dysfunction – a randomized and controlled pilot trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00029724
Enrollment
20
Registered
2022-08-03
Start date
2023-04-12
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular joint dysfunction K07.6

Interventions

Group 1: Intervention group: The taVNS is performed on the tragus of the right ear according to the device approval. A stimulation frequency of 25hz and a puls width of 250µs in an on/off-scheme (28s

Sponsors

Heinrich-Heine-Universität Düsseldorf
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria will consider the following: - Chronic Temporomandibular disorders (TMD) - Age >18 years - Provided written informed consent to participate in the trial - Positive response to the question, "Do you have pain in the right side of your face, the left side, or both?" - Grade III or IV of the Graduation of Chronic Pain Scale (GCPS) - No depression or a depression that has been stably treated for 4 weeks

Exclusion criteria

Exclusion criteria: The exclusion criteria will consider the following: - Orofacial pain or diagnosis(es) that do not qualify as myalgia, myofascial pain, or arthralgia based on the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) - Severe neurological disorders such as schizophrenia - Interventions with vagus nerve stimulation or history of vagotomy - History of relevant cardiac diseases: bradycardic arrhythmia (e.g. sick sinus syndrome), heart failure, condition after myocardial infarction - Active implant, such as pacemaker, defibrillator, neurostimulator, cochlear implant or drug delivery device, and ventricular shunt - Inability to understand the study protocol - Progressive neurological disease (e.g., Parkinson's disease, MS, epilepsy) - Pregnancy - Prostate cancer - Presence of a skin condition such as infection, psoriasis, or eczema in the treatment area - Presence of any anatomical abnormality that prevents successful insertion of the ear electrode - Presence of any serious medical condition that prevents successful study participation - Acute tinnitus

Design outcomes

Primary

MeasureTime frame
The effect of the severity of pain and quality of life should be evaluated with different questionnaires.

Secondary

MeasureTime frame
As secondary outcomes the impact of the mandibular mobility and muscles activity should be recorded.

Countries

Germany

Contacts

Public ContactLea Sophia Prott

Universitätsklinikum DüsseldorfPoliklinik für Zahnärztliche Prothetik

leasophia.prott@med.uni-duesseldorf.de0211-81-044441

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026